Planning for first small molecule ApoA-I IVUS study commences
TSX Exchange Symbol: RVX
SAN DIEGO, CA and CALGARY, AB, June 19 /CNW/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce its
sponsorship in a study which will address patients with acute coronary
syndrome. Dr. Stephen J. Nicholls, M.B.B.S. Ph.D. of the Cleveland Clinic
Coordinating Center for Clinical Research will lead a team of experts
coordinating the development of a protocol for RVX-208 in a Phase 2b
intravascular ultrasound study (IVUS). Resverlogix anticipates conducting the
2b trial next year, upon completion of a successful Phase 1b/2a trial.
"The IVUS Phase 2b study is a very exciting step for our lead drug
RVX-208," said Donald J. McCaffrey, President & CEO of Resverlogix. "Our
ultimate goal is to demonstrate that RVX-208 can increase endogenous ApoA-I
production in addition to atherosclerosis regression further supporting that
RVX-208 could possibly regress the burden of atherosclerosis."
Cleveland Clinic researchers will assist in the planning and coordinating
of the trial of RVX-208, a novel small molecule that enhances the production
of ApoA-I and functional HDL. The study will seek to answer these important
scientific questions by measuring the rate of regression of coronary disease
using intravascular ultrasound (IVUS), a technique that directly measures the
amount of plaque in the coronary arteries. Recent research has illustrated
that effecting the functionality of HDL and its main protein, ApoA-I, have
promising potential to treat atherosclerosis, thereby reducing incidents of
As a leader in ApoA-I technology Resverlogix, which has several internal
ApoA-I programs, has deemed it necessary to expand its clinical team. Thus
today Resverlogix also announces the hiring of Dr. F. Allan Gordon, M.D.,
Ph.D. who will be the Company's Senior Vice President of Clinical Development.
Dr. Gordon has more than 20 years of experience as a research scientist and
clinician in cardiology.
"It is a pleasure to have an esteemed colleague such as Dr. Gordon join
our team of experts," commented Dr. Jan Johansson, M.D., Ph.D., Senior Vice
President Medical Affairs of Resverlogix. "Dr. Gordon's key strength is his
extensive and successful experience with multiple global pharmaceutical
companies in guiding drugs through the clinical development process. Dr.
Gordon will be the lead clinical scientist for our trial work."
Dr. Gordon has built up a notable career as a research and development
professional in cardiology by achieving success both in development and
research. Prior to joining Resverlogix, he was the CEO for Nile Therapeutics,
an early stage bio-pharmaceutical in cardiovascular science, particularly in
acute heart failure. Moreover, Dr. Gordon led the international development
program for Natrecor at Scios Inc, a Johnson & Johnson company. In addition to
this work in the US, he has worked with several large pharmaceutical companies
in leading positions on clinical development programs for cardiovascular
disease, including Astra-Zeneca, Bristol-Myers Squibb and Novartis.
Dr. Gordon received his M.D. and Ph.D. from the Karolinska Institute in
Sweden where he initially worked in a number of hospital settings, followed by
his position as an Associate Professor in Cardiology at the Karolinska
Institute. He has published approximately 50 articles and abstracts.
Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the body's natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e. transport of
peripheral cholesterol including that of the vessel wall to the liver for
processing. In multiple human and animal studies over-expression or repeated
infusion of ApoA-I inhibit progression and induce regression of
atherosclerosis in animals and humans.
Cardiovascular disease is the number one killer in the developed nations
according to the World Health Organization. In the United States the American
Heart Association estimates that almost 80 million American adults have one or
more types of cardiovascular disease. Nearly 2400 Americans die each day from
cardiovascular disease - that is 1 person will die every 36 seconds.
Intravascular ultrasound (IVUS) is an invasive procedure, performed along
with cardiac catheterization; a miniature sound probe (transducer) on the tip
of a coronary catheter is threaded through the coronary arteries and, using
high-frequency sound waves, produces detailed images of the interior walls of
IVUS is used to view the artery literally from the inside out making it
possible for investigators to asses the amount of disease present. In the case
of Resverlogix's 2b clinical trial it will be used to assess the amount of
disease present prior to the administration of RVX-208 to subjects as well as
assessing the amount of disease present after a course of treatment with
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and
other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases, such
as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange
(TSX:RVX). For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Email: Theresa@resverlogix.com,
Website: www.resverlogix.com; Brian Kolonick, Media Relations Manager,
Cleveland Clinic, Phone: (216) 444-0898, Email: firstname.lastname@example.org, Website: